寡复发前列腺癌患者接受[68Ga]PSMA-PET引导的转移灶定向治疗后的生化无复发生存预后风险分类
本研究纳入292例经[68Ga]PSMA-PET检出局部复发和/或盆腔淋巴结和/或最多五个远处淋巴结、骨或内脏转移的前列腺癌患者,中位随访16个月(范围0-57),以转移灶定向治疗后生化无复发生存(bRFS)为主要终点,用Cox回归和递归分割分析建立并内部验证了I至IV级预后风险分类,各级bRFS差异显著(p<0.0001)。
要点
- 复发时PSA≥0.8 ng/mL、骨转移和内脏转移与生化复发显著相关。
- I级(PSA<0.8 ng/mL、无骨转移)平均bRFS为36.3个月,II级为25.8个月。
- III级(有骨转移,PSA不限)平均bRFS为16.0个月,IV级(PSA≥0.8 ng/mL、无骨转移、有内脏转移)为5.7个月。
核心结论
- 研究建立并内部验证了PSMA-PET引导的转移灶定向治疗后bRFS的风险分类。
- PSA<0.8 ng/mL且仅有局部复发(局部复发和/或盆腔淋巴结)的患者bRFS最有希望。
- PSA≥0.8 ng/mL且仅有局部复发(局部复发和/或盆腔淋巴结)提示中间失败风险。
- 有骨转移的患者无论PSA如何均风险更高,但这些患者bRFS仍令人满意。
- 有内脏转移的患者bRFS大幅下降,此类病例的转移灶定向治疗应个体化讨论。
研究设计与样本
- 研究分析了292例经[68Ga]PSMA-PET检出局部复发和/或盆腔淋巴结和/或最多五个远处淋巴结、骨或内脏转移的患者。
- 中位随访16个月(范围0-57),主要终点为转移灶定向治疗后的生化无复发生存(bRFS)。
- 采用Cox回归分析风险因素,并纳入递归分割分析(RPA)及分类回归树方法。
主要发现
- 复发时PSA≥0.8 ng/mL、骨转移和内脏转移与生化复发显著相关。
- RPA显示五组,十倍交叉验证为0.294(SE 0.032)。
- 建立I至IV级风险分类后,各级间差异显著(p<0.0001)。
- I级(PSA<0.8 ng/mL、无骨转移)平均bRFS为36.3个月(95%CI 32.4-40.1),II级(PSA≥0.8 ng/mL、无骨转移、无内脏转移)为25.8个月(95%CI 22.5-29.1)。
- I级和II级中局部复发和/或盆腔淋巴结导致复发;III级(有骨转移,PSA不限)平均bRFS为16.0个月(95%CI 12.4-19.6),IV级(PSA≥0.8 ng/mL、无骨转移、有内脏转移)为5.7个月(95%CI 2.7-8.7)。
关键数值与推荐
- 风险分类I级:PSA<0.8 ng/mL且无骨转移,平均bRFS 36.3个月(95%CI 32.4-40.1)。
- 风险分类II级:PSA≥0.8 ng/mL、无骨转移、无内脏转移,平均bRFS 25.8个月(95%CI 22.5-29.1)。
- 风险分类III级:有骨转移,PSA不限,平均bRFS 16.0个月(95%CI 12.4-19.6)。
- 风险分类IV级:PSA≥0.8 ng/mL、无骨转移、有内脏转移,平均bRFS 5.7个月(95%CI 2.7-8.7)。
临床怎么用
- 对于PSMA-PET引导的转移灶定向治疗后患者,可按PSA水平、骨转移和内脏转移进行I至IV级风险分层以评估bRFS。
- 有内脏转移的患者bRFS大幅下降,转移灶定向治疗应个体化讨论。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Since the success of prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging for patients with oligorecurrent prostate cancer (ORPC), it is increasingly used for radiotherapy as metastasis-directed therapy (MDT). Therefore, we developed a prognostic risk classification for biochemical relapse-free survival (bRFS) for patients after PSMA-PET-guided MDT after radical prostatectomy. METHODS: We analyzed 292 patients with local recurrence (LR) and/or pelvic lymph node (LN) lesions and/or up to five distant LN, bone (BM), or visceral metastases (VM) detected with [68Ga]PSMA-PET imaging. Median follow-up was 16 months (range 0-57). The primary endpoint was bRFS after MDT. Cox regression analysis for risk factors was incorporated into a recursive partitioning analysis (RPA) with classification and regression tree method. RESULTS: PSA at recurrence ≥ 0.8 ng/mL, BM, and VM was significantly associated with biochemical relapse. RPA showed five groups with tenfold cross-validation of 0.294 (SE 0.032). After building risk classes I to IV (p < 0.0001), mean bRFS was 36.3 months (95% CI 32.4-40.1) in class I (PSA < 0.8 ng/mL, no BM) and 25.8 months (95% CI 22.5-29.1) in class II (PSA ≥ 0.8 ng/mL, no BM, no VM). LR and/or pelvic LNs caused relapse in classes I and II. Mean bRFS was 16.0 months (95% CI 12.4-19.6) in class III (PSA irrelevant, present BM) and 5.7 months (95% CI 2.7-8.7) in class IV (PSA ≥ 0.8 ng/mL, no BM, present VM). CONCLUSION: We developed and internally validated a risk classification for bRFS after PSMA-PET-guided MDT. Patients with PSA < 0.8 ng/mL and local relapse only (LR and/or pelvic LNs) had the most promising bRFS. PSA ≥ 0.8 ng/mL and local relapse only (LR and/or pelvic LNs) indicated intermediate risk for failure. Patients with BM were at higher risk regardless of the PSA. However, those patients still show satisfactory bRFS. In patients with VM, bRFS is heavily decreased. MDT in such cases should be discussed individually.
引用
- Vogel MME, Kroeze SGC, Henkenberens C, et al. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 32179961. doi:10.1007/s00259-020-04760-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。